ArticleTranslational lung cancer research2025
Synergistic camrelizumab therapy inhibits P53-mutant osimertinib-resistant solid lung adenocarcinoma via the TGF-β signaling pathway.
Xiaoqin Shi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.